| pubmed-article:12075746 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12075746 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:12075746 | lifeskim:mentions | umls-concept:C0332174 | lld:lifeskim |
| pubmed-article:12075746 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:12075746 | lifeskim:mentions | umls-concept:C0086960 | lld:lifeskim |
| pubmed-article:12075746 | lifeskim:mentions | umls-concept:C1521801 | lld:lifeskim |
| pubmed-article:12075746 | lifeskim:mentions | umls-concept:C0067099 | lld:lifeskim |
| pubmed-article:12075746 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:12075746 | pubmed:dateCreated | 2002-6-21 | lld:pubmed |
| pubmed-article:12075746 | pubmed:abstractText | Cystemustine is a chloroethylnitrosourea mostly active in humans against glioma and melanoma. The present report describes the results of a new phase I trial with cystemustine administered on a weekly schedule. The pharmacokinetic and pharmacodynamic properties of cystemustine were investigated. | lld:pubmed |
| pubmed-article:12075746 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12075746 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12075746 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12075746 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12075746 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12075746 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12075746 | pubmed:month | May | lld:pubmed |
| pubmed-article:12075746 | pubmed:issn | 0923-7534 | lld:pubmed |
| pubmed-article:12075746 | pubmed:author | pubmed-author:ArmandJ PJP | lld:pubmed |
| pubmed-article:12075746 | pubmed:author | pubmed-author:MaurizisJ CJC | lld:pubmed |
| pubmed-article:12075746 | pubmed:author | pubmed-author:MadelmontJ... | lld:pubmed |
| pubmed-article:12075746 | pubmed:author | pubmed-author:CuréHH | lld:pubmed |
| pubmed-article:12075746 | pubmed:author | pubmed-author:LabarrePP | lld:pubmed |
| pubmed-article:12075746 | pubmed:author | pubmed-author:TerretCC | lld:pubmed |
| pubmed-article:12075746 | pubmed:author | pubmed-author:OuabdesselamR... | lld:pubmed |
| pubmed-article:12075746 | pubmed:author | pubmed-author:MarchenayCC | lld:pubmed |
| pubmed-article:12075746 | pubmed:author | pubmed-author:CellarierEE | lld:pubmed |
| pubmed-article:12075746 | pubmed:author | pubmed-author:ChollePP | lld:pubmed |
| pubmed-article:12075746 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12075746 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:12075746 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12075746 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12075746 | pubmed:pagination | 760-9 | lld:pubmed |
| pubmed-article:12075746 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12075746 | pubmed:meshHeading | pubmed-meshheading:12075746... | lld:pubmed |
| pubmed-article:12075746 | pubmed:meshHeading | pubmed-meshheading:12075746... | lld:pubmed |
| pubmed-article:12075746 | pubmed:meshHeading | pubmed-meshheading:12075746... | lld:pubmed |
| pubmed-article:12075746 | pubmed:meshHeading | pubmed-meshheading:12075746... | lld:pubmed |
| pubmed-article:12075746 | pubmed:meshHeading | pubmed-meshheading:12075746... | lld:pubmed |
| pubmed-article:12075746 | pubmed:meshHeading | pubmed-meshheading:12075746... | lld:pubmed |
| pubmed-article:12075746 | pubmed:meshHeading | pubmed-meshheading:12075746... | lld:pubmed |
| pubmed-article:12075746 | pubmed:meshHeading | pubmed-meshheading:12075746... | lld:pubmed |
| pubmed-article:12075746 | pubmed:meshHeading | pubmed-meshheading:12075746... | lld:pubmed |
| pubmed-article:12075746 | pubmed:meshHeading | pubmed-meshheading:12075746... | lld:pubmed |
| pubmed-article:12075746 | pubmed:meshHeading | pubmed-meshheading:12075746... | lld:pubmed |
| pubmed-article:12075746 | pubmed:meshHeading | pubmed-meshheading:12075746... | lld:pubmed |
| pubmed-article:12075746 | pubmed:meshHeading | pubmed-meshheading:12075746... | lld:pubmed |
| pubmed-article:12075746 | pubmed:meshHeading | pubmed-meshheading:12075746... | lld:pubmed |
| pubmed-article:12075746 | pubmed:meshHeading | pubmed-meshheading:12075746... | lld:pubmed |
| pubmed-article:12075746 | pubmed:meshHeading | pubmed-meshheading:12075746... | lld:pubmed |
| pubmed-article:12075746 | pubmed:meshHeading | pubmed-meshheading:12075746... | lld:pubmed |
| pubmed-article:12075746 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12075746 | pubmed:articleTitle | Pharmacokinetic study of cystemustine, administered on a weekly schedule in cancer patients. | lld:pubmed |
| pubmed-article:12075746 | pubmed:affiliation | Unité d'Oncothérapie Appliquée, Centre Jean Perrin, Clermont-Ferrand, France. recherche.clinique@cjp.u-clermont1.fr | lld:pubmed |
| pubmed-article:12075746 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12075746 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12075746 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:12075746 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12075746 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12075746 | lld:pubmed |
